MedPath

Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: Analysis of molecular alterations by a randomized controlled trial

Not Applicable
Conditions
Early gastric cancer or adenoma
Registration Number
JPRN-UMIN000006206
Lead Sponsor
Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Patients with malignancy in other organs (2)Patients with having allergy to drugs used for H. pylori eradication (3)Past episode of H. pylori treatment (4)Patients with regularly taking non-steroidal anti-inflammatory drugs (5)Patients with having a past history of esophagectomy or gastrectomy (6)Patients who have determined by the physicians to have any reasons of unqualified

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes of biomarkers related to carcinogenesis are evaluated at baseline and 1-yr after intervention with/without H. pylori eradication Primary endpoint: Change of microsatellite instability
Secondary Outcome Measures
NameTimeMethod
Secondary endpoint: Changes of promoter hypermethylation of some tumor-related genes
© Copyright 2025. All Rights Reserved by MedPath